JP2019515888A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515888A5 JP2019515888A5 JP2018551293A JP2018551293A JP2019515888A5 JP 2019515888 A5 JP2019515888 A5 JP 2019515888A5 JP 2018551293 A JP2018551293 A JP 2018551293A JP 2018551293 A JP2018551293 A JP 2018551293A JP 2019515888 A5 JP2019515888 A5 JP 2019515888A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- dexamethasone
- patient
- cellular immunotherapy
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 26
- 229960003957 dexamethasone Drugs 0.000 claims description 15
- 239000003862 glucocorticoid Substances 0.000 claims description 13
- 229960004618 prednisone Drugs 0.000 claims description 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims 32
- 238000009169 immunotherapy Methods 0.000 claims 15
- 230000001413 cellular effect Effects 0.000 claims 14
- 210000004698 lymphocyte Anatomy 0.000 claims 13
- 238000011467 adoptive cell therapy Methods 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 230000000779 depleting effect Effects 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 210000000987 immune system Anatomy 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 230000001093 anti-cancer Effects 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 210000004324 lymphatic system Anatomy 0.000 claims 4
- 238000001959 radiotherapy Methods 0.000 claims 4
- 238000009825 accumulation Methods 0.000 claims 3
- 229940125721 immunosuppressive agent Drugs 0.000 claims 3
- 239000003018 immunosuppressive agent Substances 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- 102000003812 Interleukin-15 Human genes 0.000 claims 2
- 108090000172 Interleukin-15 Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000000704 Interleukin-7 Human genes 0.000 claims 2
- 108010002586 Interleukin-7 Proteins 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 238000002659 cell therapy Methods 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 230000000977 initiatory effect Effects 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 claims 1
- 229960001810 meprednisone Drugs 0.000 claims 1
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960002537 betamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- 241001416152 Bos frontalis Species 0.000 description 1
- 229940117965 Glucocorticoid receptor modulator Drugs 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762480414P | 2017-04-01 | 2017-04-01 | |
| US62/480,414 | 2017-04-01 | ||
| US201862613697P | 2018-01-04 | 2018-01-04 | |
| US62/613,697 | 2018-01-04 | ||
| US201862624454P | 2018-01-31 | 2018-01-31 | |
| US62/624,454 | 2018-01-31 | ||
| PCT/US2018/025517 WO2018183927A1 (en) | 2017-04-01 | 2018-03-30 | Replacement of cytotoxic preconditioning before cellular immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020049116A Division JP7162632B2 (ja) | 2017-04-01 | 2020-03-19 | 細胞免疫療法前の細胞毒性プレコンディショニングの代替 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515888A JP2019515888A (ja) | 2019-06-13 |
| JP2019515888A5 true JP2019515888A5 (cg-RX-API-DMAC10.html) | 2019-11-28 |
| JP6748221B2 JP6748221B2 (ja) | 2020-08-26 |
Family
ID=62111173
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551293A Active JP6748221B2 (ja) | 2017-04-01 | 2018-03-30 | 細胞免疫療法前の細胞毒性プレコンディショニングの代替 |
| JP2020049116A Active JP7162632B2 (ja) | 2017-04-01 | 2020-03-19 | 細胞免疫療法前の細胞毒性プレコンディショニングの代替 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020049116A Active JP7162632B2 (ja) | 2017-04-01 | 2020-03-19 | 細胞免疫療法前の細胞毒性プレコンディショニングの代替 |
Country Status (13)
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10426740B1 (en) | 2010-08-18 | 2019-10-01 | Avm Biotechnology, Llc | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
| WO2025019711A2 (en) * | 2023-07-19 | 2025-01-23 | Dermtech, Inc. | Predicting therapeutic response based on biomarker signatures |
| CN110475571B (zh) | 2017-04-01 | 2023-04-04 | Avm生物技术有限责任公司 | 细胞免疫疗法前细胞毒性预调理的替代 |
| CN110944689B (zh) | 2017-06-07 | 2022-12-09 | 施菲姆德控股有限责任公司 | 血管内流体运动设备、系统和使用方法 |
| WO2019094963A1 (en) | 2017-11-13 | 2019-05-16 | Shifamed Holdings, Llc | Intravascular fluid movement devices, systems, and methods of use |
| WO2019152875A1 (en) | 2018-02-01 | 2019-08-08 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of use and manufacture |
| KR20210011919A (ko) | 2018-04-17 | 2021-02-02 | 셀덱스 쎄라퓨틱스, 인크. | 항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물 |
| US12161857B2 (en) | 2018-07-31 | 2024-12-10 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of use |
| EP3488851A1 (en) | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| EP3632446B3 (en) | 2018-10-03 | 2024-01-24 | AVM Biotechnology, LLC | Immunoablative therapies |
| WO2020073047A1 (en) | 2018-10-05 | 2020-04-09 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of use |
| BR112021009365A2 (pt) * | 2018-11-14 | 2021-08-10 | Avm Biotechnology, Llc | formulação de glicocorticoide estável |
| KR102946444B1 (ko) * | 2018-11-16 | 2026-04-02 | 라파 쎄라퓨틱스 엘엘씨 | 제조된 t 세포로 암을 치료하는 방법 |
| US20220016168A1 (en) * | 2018-12-11 | 2022-01-20 | Celldex Therapeutics, Inc. | Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy |
| KR20250116790A (ko) | 2018-12-12 | 2025-08-01 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 및 car-t 세포 및 사용 방법 |
| US11964145B2 (en) | 2019-07-12 | 2024-04-23 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of manufacture and use |
| WO2021016372A1 (en) | 2019-07-22 | 2021-01-28 | Shifamed Holdings, Llc | Intravascular blood pumps with struts and methods of use and manufacture |
| EP4010046B1 (en) | 2019-08-07 | 2026-07-15 | Supira Medical, Inc. | Catheter blood pumps and collapsible pump housings |
| WO2021062270A1 (en) | 2019-09-25 | 2021-04-01 | Shifamed Holdings, Llc | Catheter blood pumps and collapsible pump housings |
| EP4782050A1 (en) | 2019-09-25 | 2026-07-29 | Supira Medical, Inc. | Catheter blood pumps and collapsible blood conduits |
| EP4034192B1 (en) | 2019-09-25 | 2025-12-24 | Supira Medical, Inc. | Intravascular blood pump systems and methods of use and control thereof |
| IL292665B2 (en) * | 2019-11-06 | 2026-02-01 | Kite Pharma Inc | Chimeric antigen receptor T cell therapy |
| EP4072650A4 (en) | 2019-12-11 | 2024-01-10 | Shifamed Holdings, LLC | Descending aorta and vena cava blood pumps |
| WO2021127503A1 (en) | 2019-12-19 | 2021-06-24 | Shifamed Holdings, Llc | Intravascular blood pumps, motors, and fluid control |
| CN113189340A (zh) * | 2020-01-14 | 2021-07-30 | 中国医学科学院基础医学研究所 | 细胞焦亡通路在细胞治疗中的用途 |
| WO2021168375A1 (en) * | 2020-02-20 | 2021-08-26 | Kite Pharma, Inc. | Chimeric antigen receptor t cell therapy |
| KR20220148859A (ko) | 2020-02-28 | 2022-11-07 | 에이브이엠 바이오테크놀로지, 엘엘씨 | 림프구 집단 및 이를 생산하는 방법 |
| CN111443210B (zh) * | 2020-04-10 | 2023-09-22 | 青海大学附属医院 | 泡型包虫病早期诊疗生物标志物及其应用 |
| CN115989038A (zh) * | 2020-04-10 | 2023-04-18 | 北卡罗莱纳州立大学 | 使用材料支架的增强的哺乳动物细胞病毒转导 |
| US20230172950A1 (en) | 2020-04-29 | 2023-06-08 | Avm Biotechnology, Llc | Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus |
| WO2021231806A1 (en) | 2020-05-13 | 2021-11-18 | Rapa Therapeutics, Llc | Antigen presenting t cells, sensitized, manufactured t cells and methods of treatment using the same |
| WO2021247000A1 (en) | 2020-06-01 | 2021-12-09 | Avm Biotechnology, Llc | Methods of treatment using icam-modulating agents |
| CN113797313A (zh) * | 2020-06-11 | 2021-12-17 | 华北制药集团新药研究开发有限责任公司 | 卡非佐米作为冠状病毒广谱抑制剂的新用途 |
| WO2022049572A1 (en) * | 2020-09-01 | 2022-03-10 | The National Institute for Biotechnology in the Negev Ltd. | Immune system restoration by cell therapy |
| CN113322233A (zh) * | 2021-04-19 | 2021-08-31 | 格源致善(上海)生物科技有限公司 | 一种改进的基于新生抗原反应性t细胞的制备方法及应用 |
| EP4326286A4 (en) * | 2021-04-23 | 2025-03-12 | Myeloid Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR CONDITIONING PATIENTS FOR CELL THERAPY |
| CN115947793B (zh) * | 2021-08-13 | 2023-09-26 | 中国人民解放军总医院 | 靶向pd-l1的超高亲和力小蛋白及用途 |
| CA3229529A1 (en) | 2021-09-01 | 2023-03-09 | Avm Biotechnology, Llc | Lymphocyte population and methods for producing same |
| CN114031678A (zh) * | 2021-12-08 | 2022-02-11 | 中国科学院新疆理化技术研究所 | 一种条斑钳蝎毒素多肽组分的制备方法及其应用 |
| CN114767828A (zh) * | 2022-04-25 | 2022-07-22 | 中国人民解放军海军军医大学 | 伊沙佐米在制备抗蜱传脑炎病毒、西尼罗病毒、黄热病毒和基孔肯雅热病毒感染药物中的应用 |
| CN115785203B (zh) * | 2022-06-10 | 2024-03-12 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标10及其用途 |
| CN116606352B (zh) * | 2023-07-14 | 2023-09-29 | 诺赛联合(北京)生物医学科技有限公司 | 一种抗菌修复功能的组合物凝胶在妇科疾病中的应用 |
| WO2025043547A1 (zh) | 2023-08-30 | 2025-03-06 | 杭州高田生物医药有限公司 | T细胞导向免疫脂质体及其用途 |
| KR20250139235A (ko) | 2025-07-15 | 2025-09-23 | 김종구 | V-aemi 기반 인공지능 감정 음악 창작 시스템 및 그 방법 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
| GB9323199D0 (en) | 1993-11-10 | 1994-01-05 | Falkenberg J H F | Leukaemia treatment |
| ES2324334T3 (es) * | 1997-12-16 | 2009-08-05 | University Of Zurich | Productos terapeuticos para las celulas t para la encefalopatia espongiforme transmisible y metodo para la fabricacion de productos derivados de tejidos y fluidos corporales no infecciosos. |
| US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
| US20030099621A1 (en) * | 2001-11-29 | 2003-05-29 | Robert Chow | Stem cell screening and transplantation therapy for HIV infection |
| IL146970A0 (en) | 2001-12-06 | 2002-08-14 | Yeda Res & Dev | Migration of haematopoietic stem cells and progenitor cells to the liver |
| US7282222B2 (en) | 2002-03-15 | 2007-10-16 | The United States Of America As Represented By The Department Of Veterans Affairs | Methods and compositions for directing cells to target organs |
| DK1505973T3 (da) | 2002-05-17 | 2010-05-31 | Celgene Corp | Kombinationer til behandling af multipelt myelom |
| GB0310593D0 (en) | 2003-05-08 | 2003-06-11 | Leuven K U Res & Dev | Peptidic prodrugs |
| US20040247574A1 (en) | 2003-05-27 | 2004-12-09 | Christopherson Kent W. | Methods for enhancing stem cell engraftment during transplantation |
| CA2589063C (en) | 2004-12-23 | 2016-08-09 | DePuy Synthes Products, Inc. | Treatment of parkinson's disease and related disorders using postpartum derived cells |
| CA2606081C (en) * | 2005-04-26 | 2013-09-17 | Markus M. Heiss | Combination of the application of antibodies for immunostimulation together with glucocorticoids |
| RU2486204C2 (ru) | 2005-07-22 | 2013-06-27 | Уай'З Терапьютикс Ко., Лтд. | Антитела против сd26 и способы их применения |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
| WO2008094689A2 (en) | 2007-02-01 | 2008-08-07 | Nephrogen, Llc | Potentiation of stem cell homing and treatment of organ dysfunction or organ failure |
| WO2009142759A1 (en) | 2008-05-23 | 2009-11-26 | Argos Therapeutics, Inc. | Novel soluble cd83 polypeptides, formulations and methods of use |
| US20090299269A1 (en) | 2008-05-29 | 2009-12-03 | John Foley | Vascular stimulation to aid intravascular cell replacement therapy |
| ES2627043T3 (es) | 2008-06-09 | 2017-07-26 | Targazyme, Inc. | Aumento de la eficacia de la terapia celular incluyendo tratamiento con alfa 1-3 fucoslitransferasa |
| WO2009152186A1 (en) | 2008-06-09 | 2009-12-17 | American Stem Cell, Inc. | Methods for enhancing cell therapy efficacy including treatment with cd26 peptidase inhibitors |
| US20100055107A1 (en) * | 2008-07-31 | 2010-03-04 | Defu Zeng | Methods for preventing hematological malignancies and graft versus host disease by anti-cd3 preconditioning |
| US10426740B1 (en) * | 2010-08-18 | 2019-10-01 | Avm Biotechnology, Llc | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
| BR112013003169B1 (pt) * | 2010-08-18 | 2022-05-24 | Theresa Deisher | Uso de um agente terapêutico que inibe a ligação de células-tronco a tecido linfóide |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP2014509841A (ja) | 2011-01-18 | 2014-04-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するための組成物および方法 |
| EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
| KR20140060541A (ko) | 2011-09-16 | 2014-05-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 rna 조작된 t 세포 |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| SG10202109752XA (en) * | 2014-04-07 | 2021-10-28 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
| EP3250602A1 (en) * | 2015-01-26 | 2017-12-06 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
| KR102349677B1 (ko) * | 2015-05-28 | 2022-01-12 | 카이트 파마 인코포레이티드 | T 세포 요법을 위해 환자를 컨디셔닝하는 방법 |
| AU2017368248A1 (en) * | 2016-11-30 | 2019-06-06 | Intrexon Corporation | Steroid administration and immunotherapy |
| CN110475571B (zh) | 2017-04-01 | 2023-04-04 | Avm生物技术有限责任公司 | 细胞免疫疗法前细胞毒性预调理的替代 |
| EP3488851A1 (en) * | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
-
2018
- 2018-03-30 CN CN201880021900.0A patent/CN110475571B/zh active Active
- 2018-03-30 IL IL269209A patent/IL269209B2/en unknown
- 2018-03-30 EP EP18722262.5A patent/EP3490605B1/en active Active
- 2018-03-30 WO PCT/US2018/025517 patent/WO2018183927A1/en not_active Ceased
- 2018-03-30 BR BR112019020214-5A patent/BR112019020214A2/pt not_active Application Discontinuation
- 2018-03-30 CA CA3054443A patent/CA3054443A1/en active Pending
- 2018-03-30 ES ES18722262T patent/ES2954311T3/es active Active
- 2018-03-30 MX MX2019011679A patent/MX2019011679A/es unknown
- 2018-03-30 JP JP2018551293A patent/JP6748221B2/ja active Active
- 2018-03-30 KR KR1020197031661A patent/KR102509006B1/ko active Active
- 2018-03-30 SG SG11201907744QA patent/SG11201907744QA/en unknown
- 2018-03-30 AU AU2018243753A patent/AU2018243753A1/en not_active Abandoned
- 2018-05-10 US US15/976,630 patent/US11219628B2/en active Active
-
2020
- 2020-03-19 JP JP2020049116A patent/JP7162632B2/ja active Active
-
2021
- 2021-12-06 US US17/542,712 patent/US20220160729A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020114837A5 (cg-RX-API-DMAC10.html) | ||
| Wu et al. | Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model | |
| Zhang et al. | Abscopal effects with hypofractionated schedules extending into the effector phase of the tumor-specific T-cell response | |
| Yasmin-Karim et al. | Radiation and local anti-CD40 generate an effective in situ vaccine in preclinical models of pancreatic cancer | |
| Zheng et al. | Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer | |
| JP2017507155A5 (cg-RX-API-DMAC10.html) | ||
| Paolino et al. | Glucocorticoid management in rheumatoid arthritis: morning or night low dose? | |
| RU2018145184A (ru) | Pd-1 / pd-l1 ингибиторы для лечения злокачественного новообразования | |
| JP2013501731A5 (cg-RX-API-DMAC10.html) | ||
| FI3703710T3 (fi) | Menetelmiä ja koostumuksia allogeenisten kimeeristä antigeenireseptoria kantavien t-solujen annostelemiseksi refraktorisen ja/tai uusiutuneen suurisoluisen b-solulymfooman tai refraktorisen ja/tai uusiutuneen follikulaarisen lymfooman hoitamista varten | |
| RU2012109451A (ru) | Комбинированная терапия на основе афукозилированного антитела к cd20 в сочетании с флударабином и/или митоксантроном | |
| JP2020512361A5 (cg-RX-API-DMAC10.html) | ||
| US20200069680A1 (en) | Oxabicycloheptanes for modulation of immune response | |
| Sorrentino et al. | Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models | |
| Filatenkov et al. | Treatment of 4T1 metastatic breast cancer with combined hypofractionated irradiation and autologous T-cell infusion | |
| Shimoda et al. | The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia: retrospective analysis of 39 patients in Japan | |
| Mohammadi | Systemic and local applications of steroids in endodontics: an update review | |
| Kozlov et al. | Nivolumab in pediatric Hodgkin's lymphoma | |
| EP0303687B1 (en) | Compositions for enhancing adcc therapy | |
| Zinzani et al. | Hairy cell leukemia: allogeneic transplantation could be an optimal option in selected patients | |
| Ghalie et al. | Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation. | |
| Bolding | Diethylpropion hydrochloride: an effective appetite suppressant. | |
| MX2023005695A (es) | Administracion de agonista de sting, inhibidores de puntos de control y radiacion. | |
| Lissoni et al. | Thrombopoietic property of the pineal hormone melatonin | |
| Gutierrez et al. | 726 Phase I results of FT516, an off-the-shelf, iPSC-derived NK cell therapy expressing a high-affinity, non-cleavable CD16 (hnCD16) combined with avelumab in patients with advanced solid tumors |